NCT05569174 - Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2024

Conditions

Tendinopathy

Interventions

DRUG

secukinumab

AIN457 300 mg subcutaneously for 12 weeks

OTHER

Placebo

Placebo to match AIN457 subcutaneously for 12 weeks

Trial Locations (19)

10787

Novartis Investigative Site, Berlin

12627

Novartis Investigative Site, Berlin

18209

Novartis Investigative Site, Bad Doberan

20095

Novartis Investigative Site, Hamburg

20149

Novartis Investigative Site, Hamburg

22415

Novartis Investigative Site, Hamburg

30159

Novartis Investigative Site, Hanover

39218

Novartis Investigative Site, Schönebeck

44649

Novartis Investigative Site, Herne

45968

Novartis Investigative Site, Gladbeck

52525

Novartis Investigative Site, Heinsberg

55131

Novartis Investigative Site, Mainz

60313

Novartis Investigative Site, Frankfurt am Main

76133

Novartis Investigative Site, Karlsruhe

80809

Novartis Investigative Site, Munich

91054

Novartis Investigative Site, Erlangen

03042

Novartis Investigative Site, Cottbus

01069

Novartis Investigative Site, Dresden

06120

Novartis Investigative Site, Halle S